Compensation Agreements in the Pharmaceuticals Industry
640 Contracts & Agreements
- ACELRX PHARMACEUTICALS INC (7 contracts)
- ACHILLION PHARMACEUTICALS INC (3)
- Aclaris Therapeutics, Inc. (11)
- Adamis Pharmaceuticals Corp (1)
- Aegerion Pharmaceuticals, Inc. (9)
- AEON Biopharma, Inc. (1)
- AERIE PHARMACEUTICALS INC (1)
- Aerpio Pharmaceuticals, Inc. (1)
- Akorn (1)
- ALDER BIOPHARMACEUTICALS INC (1)
- Alexza Pharmaceuticals Inc. (1)
- ALIMERA SCIENCES INC (18)
- ALSERES PHARMACEUTICALS INC (10)
- Altus Pharmaceuticals Inc. (3)
- Amag Pharmaceuticals (12)
- Amneal Pharmaceuticals, Inc. (6)
- Amphastar Pharma (1)
- AMYLIN PHARMACEUTICALS INC (2)
- Amylyx Pharmaceuticals, Inc. (3)
- AN2 Therapeutics, Inc. (2)
- Anebulo Pharmaceuticals, Inc. (1)
- Angion Biomedica Corp. (5)
- ANI Pharma Inc (7)
- Anthera Pharmaceuticals Inc (4)
- APP Pharmaceuticals, Inc. (2)
- APRICUS BIOSCIENCES, INC. (6)
- Aquestive Therapeutics, Inc. (1)
- ARIAD PHARMACEUTICALS INC (11)
- Aspreva Pharmaceuticals CORP (1)
- Assertio Holdings, Inc. (2)
- Assertio Therapeutics, Inc (3)
- Atea Pharmaceuticals, Inc. (4)
- Athira Pharma, Inc. (2)
- Auspex Pharmaceuticals, Inc. (4)
- AUXILIUM PHARMACEUTICALS INC (9)
- AVANIR PHARMACEUTICALS, INC. (2)
- Axsome Therapeutics, Inc. (1)
- BARR PHARMACEUTICALS INC (2)
- Bausch Health Companies Inc. (1)
- Biofrontera Inc. (1)
- Blue Water Acquisition Corp. (1)
- Bright Green Corp (1)
- Bristol-Myers Squibb (6)
- CADENCE PHARMACEUTICALS INC (3)
- CALLISTO PHARMACEUTICALS INC (2)
- Canbiola, Inc. (1)
- Canopy Growth Corp (4)
- Cara Therapeutics, Inc. (5)
- CARDAX, INC. (2)
- CASSAVA SCIENCES INC (4)
- Catalent Inc (5)
- Cerecor Inc. (3)
- CHIASMA, INC (2)
- Clearside Biomedical, Inc. (5)
- Clever Leaves Holdings Inc. (1)
- CNS Pharmaceuticals, Inc. (3)
- COLLAGENEX PHARMACEUTICALS INC (6)
- CoLucid Pharmaceuticals, Inc. (2)
- CUBIST PHARMACEUTICALS INC (3)
- CUMBERLAND PHARMACEUTICALS INC (1)
- CymaBay Therapeutics, Inc. (6)
- Dova Pharmaceuticals Inc. (2)
- DUSA PHARMACEUTICALS INC (3)
- Edgewise Therapeutics, Inc. (3)
- Egalet Corp (1)
- Eleison Pharmaceuticals Inc (1)
- Endo International plc (2)
- EPIX Pharmaceuticals, Inc. (1)
- Evofem Biosciences, Inc. (5)
- Evoke Pharma Inc (10)
- EYENOVIA, INC. (3)
- Foamix Pharmaceuticals Ltd. (1)
- Fulcrum Therapeutics, Inc. (3)
- GB SCIENCES INC (1)
- GUILFORD PHARMACEUTICALS INC (1)
- Harmony Biosciences Holdings, Inc. (1)
- Horizon Pharma plc (11)
- IDENIX PHARMACEUTICALS INC (2)
- Ikena Oncology, Inc. (1)
- IMARA Inc. (2)
- INNOVATE BIOPHARMACEUTICALS, INC. (2)
- INSPIRE PHARMACEUTICALS INC (10)
- IntelGenx Technologies Corp. (1)
- Intersect ENT, Inc. (6)
- Intra-Cellular Therapies, Inc. (9)
- Iterum Therapeutics plc (2)
- Jazz Pharmaceuticals plc (22)
- Johnson & Johnson (9)
- Journey Medical Corp (1)
- KEMPHARM, INC (9)
- KING PHARMACEUTICALS INC (7)
- KOS PHARMACEUTICALS INC (2)
- Landos Biopharma, Inc. (1)
- Lannett Company, Inc. (1)
- Level Brands, Inc. (1)
- Lexaria Bioscience Corp. (1)
- Lilly (Eli) & Co. (7)
- Longboard Pharmaceuticals, Inc. (3)
- Lyra Therapeutics, Inc. (1)
- MedMen Enterprises, Inc. (1)
- Menlo Therapeutics Inc. (1)
- Merck (7)
- Milestone Pharmaceuticals Inc. (6)
- MILLENNIUM PHARMACEUTICALS INC (1)
- Mind Medicine (MindMed) Inc. (2)
- MJ Holdings, Inc. (1)
- MyoKardia Inc (4)
- NEKTAR THERAPEUTICS (11)
- Neos Therapeutics, Inc. (2)
- Neuralstem, Inc. (1)
- NEW RIVER PHARMACEUTICALS INC (2)
- NGM BIOPHARMACEUTICALS INC (3)
- NovaBay Pharmaceuticals, Inc. (10)
- Novan, Inc. (8)
- NOVEN PHARMACEUTICALS INC (1)
- NPS PHARMACEUTICALS INC (3)
- NUCRYST Pharmaceuticals Corp. (1)
- OMEROS CORP (4)
- OncoMed Pharmaceuticals Inc (5)
- ONYX PHARMACEUTICALS INC (3)
- OSI PHARMACEUTICALS INC (1)
- OTONOMY, INC. (1)
- Pacira Pharmaceuticals, Inc. (2)
- Panacea Acquisition Corp (3)
- PANACOS PHARMACEUTICALS, INC. (7)
- Paratek Pharmaceuticals, Inc. (12)
- PENWEST PHARMACEUTICALS CO (3)
- Perrigo (5)
- Pfizer (18)
- Phathom Pharmaceuticals, Inc. (6)
- PLIANT THERAPEUTICS, INC. (5)
- PRAECIS PHARMACEUTICALS INC (1)
- PREDIX PHARMACEUTICALS HOLDINGS INC (1)
- Prestige Brands Holdings Inc (2)
- ProPhase Labs, Inc. (12)
- Pulmatrix, Inc. (1)
- Ra Pharmaceuticals, Inc. (2)
- Rani Therapeutics Holdings, Inc. (1)
- REATA PHARMACEUTICALS INC (6)
- Recro Pharma, Inc. (1)
- RELMADA THERAPEUTICS, INC. (4)
- resTORbio, Inc. (2)
- Revance Therapeutics, Inc. (11)
- Rib-X Pharmaceuticals, Inc. (1)
- Sagent Pharmaceuticals, Inc. (1)
- SALIX PHARMACEUTICALS LTD (2)
- Satsuma Pharmaceuticals, Inc. (1)
- scPharmaceuticals Inc. (1)
- SCYNEXIS INC (10)
- Sienna Biopharmaceuticals, Inc. (2)
- Strongbridge Biopharma plc (4)
- Sucampo Pharmaceuticals, Inc. (3)
- SUNWIN STEVIA INTERNATIONAL, INC. (2)
- TAPESTRY PHARMACEUTICALS, INC (1)
- Targeted Medical Pharma, Inc. (1)
- Terns Pharmaceuticals, Inc. (4)
- TEVA PHARMACEUTICAL INDUSTRIES LTD (1)
- The Medicines Company (4)
- TherapeuticsMD, Inc. (2)
- Theseus Pharmaceuticals, Inc. (2)
- Trevi Therapeutics, Inc. (2)
- Tribute Pharmaceuticals Canada Inc. (1)
- Vallon Pharmaceuticals, Inc. (2)
- Ventyx Biosciences, Inc. (1)
- Verrica Pharmaceuticals Inc. (4)
- VioQuest Pharmaceuticals, Inc. (1)
- Vitae Pharmaceuticals, Inc (1)
- Vyrix Pharmaceuticals, Inc. (1)
- Wave Life Sciences Ltd. (8)
- XANODYNE PHARMACEUTICALS INC (1)
- XERIS PHARMACEUTICALS INC (1)
- Zoetis (2)
- ZOGENIX, INC. (8)
- Zomedica Pharmaceuticals Corp. (1)
- Zynerba Pharmaceuticals, Inc. (2)
- Retention Compensation Agreement, effective as of August 27, 2024, between Relmada Therapeutics, Inc. and Paul Kelly (RELMADA THERAPEUTICS, INC., Filed With SEC on January 6, 2025)
- Retention Compensation Agreement, effective as of August 27, 2024, between Relmada Therapeutics, Inc. and Charles Ence (RELMADA THERAPEUTICS, INC., Filed With SEC on January 6, 2025)
- Retention Compensation Agreement, effective as of August 27, 2024, between Relmada Therapeutics, Inc. and Maged Shenouda (RELMADA THERAPEUTICS, INC., Filed With SEC on January 6, 2025)
- Retention Compensation Agreement, effective as of August 27, 2024, between Relmada Therapeutics, Inc. and Sergio Traversa (RELMADA THERAPEUTICS, INC., Filed With SEC on January 6, 2025)
- Non-Employee Director Compensation Policy, effective as of August 6, 2024 (Wave Life Sciences Ltd., Filed With SEC on November 12, 2024)
- Non-Employee Director Compensation Policy, as amended July 11, 2024 (Milestone Pharmaceuticals Inc., Filed With SEC on November 12, 2024)
- Non-Employee Director Compensation Policy, Amended June 6, 2024 with an effective date of July 1, 2024 (Cerecor Inc., Filed With SEC on November 7, 2024)
- Compensation Plan Agreement, dated October 25, 2024 between Can B Corp. and Can B Corp (Canbiola, Inc., Filed With SEC on October 28, 2024)
- Amended and Restated Outside Director Compensation Policy, adopted April 3, 2024 (Ventyx Biosciences, Inc., Filed With SEC on August 8, 2024)
- Amended and Restated Non-Employee Director Compensation Program (Phathom Pharmaceuticals, Inc., Filed With SEC on August 8, 2024)
- NonEmployee Director Compensation and Grant Policy (Assertio Holdings, Inc., Filed With SEC on August 7, 2024)
- Non-Employee Director Compensation Program (Atea Pharmaceuticals, Inc., Filed With SEC on August 7, 2024)
- Amended and Restated Outside Director Compensation Plan (Aerpio Pharmaceuticals, Inc., Filed With SEC on August 7, 2024)
- Non-Employee Director Compensation Policy (Longboard Pharmaceuticals, Inc., Filed With SEC on August 1, 2024)
- Non-Employee Director Compensation Table (Canopy Growth Corp, Filed With SEC on May 30, 2024)
- Non-Employee Director Compensation Policy (AN2 Therapeutics, Inc., Filed With SEC on May 14, 2024)
- Non-Employee Director Compensation Policy (Panacea Acquisition Corp, Filed With SEC on May 14, 2024)
- Second Amended and Restated Non-Employee Director Compensation Program (Terns Pharmaceuticals, Inc., Filed With SEC on May 13, 2024)
- Non-Employee Director Compensation Policy, as amended (Milestone Pharmaceuticals Inc., Filed With SEC on May 13, 2024)
- Amended and Restated Non-Employee Director Compensation Policy (Clearside Biomedical, Inc., Filed With SEC on May 10, 2024)
- Amended and Restated Outside Director Compensation Policy (Edgewise Therapeutics, Inc., Filed With SEC on May 9, 2024)
- Amended and Restated Non-Employee Director Compensation Policy (Amylyx Pharmaceuticals, Inc., Filed With SEC on May 9, 2024)
- Revance Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy (Revance Therapeutics, Inc., Filed With SEC on May 9, 2024)
- Non-Employee Director Compensation Policy, as amended (SCYNEXIS INC, Filed With SEC on May 8, 2024)
- Non-Employee Director Compensation Policy, as amended (Intra-Cellular Therapies, Inc., Filed With SEC on May 7, 2024)
- Amended and Restated Non-Employee Director Compensation Policy (approved April 25, 2024) (Jazz Pharmaceuticals plc, Filed With SEC on May 2, 2024)
- Non-Employee Director Compensation Policy (SCYNEXIS INC, Filed With SEC on March 28, 2024)
- 2024 Non-Employee Director Compensation Plan (NovaBay Pharmaceuticals, Inc., Filed With SEC on March 26, 2024)
- Outside Director Compensation Policy, as amended February 13, 2024 (IMARA Inc., Filed With SEC on March 14, 2024)
- Amended and Restated Non-Employee Director Compensation Policy (scPharmaceuticals Inc., Filed With SEC on March 13, 2024)
- Non-Employee Director Compensation Policy (Menlo Therapeutics Inc., Filed With SEC on March 1, 2024)
- Second Amended and Restated Non-Employee Director Compensation Policy, adopted by the Board as of February 27, 2024 (Verrica Pharmaceuticals Inc., Filed With SEC on February 29, 2024)
- Amended and Restated Non-Employee Director Compensation Policy (PLIANT THERAPEUTICS, INC., Filed With SEC on February 27, 2024)
- Amendment No. 4 to Amended and Restated Deferred Compensation Plan (Pfizer, Filed With SEC on February 22, 2024)
- Non-Employee Director Compensation Program (CymaBay Therapeutics, Inc., Filed With SEC on January 26, 2024)
- Amended and Restated Non-Employee Director Compensation Program (Vallon Pharmaceuticals, Inc., Filed With SEC on December 4, 2023)
- Johnson & Johnson Deferred Compensation Plan (Johnson & Johnson, Filed With SEC on November 27, 2023)
- Non-Employee Director Compensation Program (Angion Biomedica Corp., Filed With SEC on November 13, 2023)
- Non-Employee Director Compensation Policy, as amended (Milestone Pharmaceuticals Inc., Filed With SEC on November 13, 2023)
- Non-Employee Director Compensation Policy, effective as of August 7, 2023 (Wave Life Sciences Ltd., Filed With SEC on November 9, 2023)
